To the Editor
We read with great interest the article by Pozdnyakova et al, 1 particularly in dealing with the proposal for a new flow cytometric criterion for bone marrow (BM) involvement in systemic mastocytosis (SM), as defined by the observation of a discrete population of CD117 bright mast cells (MCs). The authors claim that this new criterion could increase the sensitivity of the immunophenotypic criterion proposed by the World Health Organization for the analysis of their BM samples from SM patients, without harming specificity. However, we noted some apparent inconsistencies in the article with regard to the exact numbers of BM samples and SM cases analyzed, while at the same time few negative control samples were studied to definitively prove the specificity of the new proposed criterion. In addition, Pozdnyakova et al 1 also include in their article a high percentage (11/39; 28%) of SM cases, which showed a rather uncommon CD2-, CD25-immunophenotype. These 3 points are discussed below in more detail.
First, a careful analysis of both the text and the tables shows major inconsistencies with regard to the exact number of SM patients (and samples) studied by Pozdnyakova et al. 1 Were 39 patients studied, as listed in Table 4 , or 23, as detailed in Table 1 ? In fact, the numbers do not match even if we consider together cases with SM (n = 23) and monoclonal MC activation syndromes (n = 8), as listed in Table 1 . In addition, Pozdnyakova et al do not specify in which SM cases multiple studies were performed, and there is no information about study time points (eg, whether patients had received any therapy prior to the study).
Second, with regard to the newly proposed diagnostic criterion, the observation of a discrete MC population in fact just reflects an increased percentage of MCs in the sample, and it could be more objectively evaluated as such. Based on our extensive experience, an increased percentage of BM MCs translating into a discrete MC population on multiparameter flow cytometry immunophenotypic grounds is frequently observed in multiple disease conditions other than SM ❚Figure 1❚ and ❚Table 1❚; this turns into a variable but low specificity, depending on the specific disease conditions evaluated (Table 1) . Among others, these include chronic lymphoproliferative disorders (eg, Waldenström macroglobulinemia), myelodysplastic syndrome (MDS), regenerating BM after chemotherapy, chronic eosinophilic leukemia, myeloproliferative neoplasms, BM aplasia, reactive/regenerating BM associated with cytopenias (reviewed in Escribano et al 2 ) , and even normal BM samples (Table 1) . Although Pozdnyakova et al 1 reported that they analyzed several cases of B-cell chronic lymphoproliferative disorder, they only state that among these cases, MCs were systematically negative for CD2 and CD25 without providing information about the potential coexistence (which frequently occurs) of a discrete population of BM MCs ( Figure 1 and Table 1 ).
Finally, among those 39 SM cases listed in Table 4 , the authors report 11 cases to have CD2-, CD25-BM MCs. Previous studies have shown that such a phenotype is typically restricted to a very small group of SM cases, usually lacking activating mutations of KIT and corresponding to the so-called well-differentiated SM variant. [3] [4] [5] Although the authors do not report about the specific flow cytometric approach used in their study, it becomes clear that this did not adhere to recommended standardized multiparameter flow cytometry approaches for immunophenotyping of BM MCs from SM. As an example, only CD117 (in the absence of CD45) was used to gate BM MCs, and more important, no sensitive fluorochromes (eg, phycoerythrin) were used to stain dimly expressed markers such as CD2 6 and CD25. 7, 8 Because of this, it becomes uncertain whether those 11 cases really correspond to CD25-, CD2-SM or are false-negative cases due to the low sensitivity of the fluorochrome antibody conjugate used. This could be clarified if the authors provide the precise diagnostic subtype and the features for each diagnostic criterion observed for each individual case. Please note that ❚Figure 1❚ Representative dot plots from bone marrow samples from 2 different patients presenting a discrete mast cell population, as defined by Pozdnyakova et al. 1 A, Systemic mastocytosis with 0.5% of infiltrating CD25+ and CD2+ mast cells. B, A bone marrow sample from a patient with myelodysplastic syndrome showing 0.37% phenotypically normal (CD25-, CD2-) mast cells. PE, phycoerythrin; SSC, side scatter. On the basis of all the above, we sincerely believe that the recommendations made by Pozdnyakova et al 1 about the potential utility of the newly proposed phenotypic criterion are not supported by our findings, as well as by the authors' data, and that the observation of a discrete BM MC population should not be viewed as a specific diagnostic criterion for SM. In turn, the recommendations reported in the literature for sensitive flow cytometric evaluation of BM MCs should be strictly followed to prevent false-negative results in the flow cytometry immunophenotypic diagnostic workup of SM patients.
❚Table 1❚ Percentage of Bone Marrow Mast Cells as Analyzed by Highly Sensitive Multiparameter Flow Cytometry in Systemic Mastocytosis vs Healthy Adults and Different Disease Conditions Other Than Mastocytosis

